Foghorn Therapeutics (FHTX) Operating Expenses: 2020-2025
Historic Operating Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to $26.7 million.
- Foghorn Therapeutics' Operating Expenses fell 15.81% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.0 million, marking a year-over-year decrease of 14.36%. This contributed to the annual value of $125.3 million for FY2024, which is 11.81% down from last year.
- Latest data reveals that Foghorn Therapeutics reported Operating Expenses of $26.7 million as of Q3 2025, which was down 6.98% from $28.7 million recorded in Q2 2025.
- Foghorn Therapeutics' Operating Expenses' 5-year high stood at $38.6 million during Q1 2023, with a 5-year trough of $23.4 million in Q1 2021.
- For the 3-year period, Foghorn Therapeutics' Operating Expenses averaged around $32.0 million, with its median value being $31.7 million (2024).
- In the last 5 years, Foghorn Therapeutics' Operating Expenses skyrocketed by 70.62% in 2021 and then declined by 15.81% in 2025.
- Foghorn Therapeutics' Operating Expenses (Quarterly) stood at $28.8 million in 2021, then increased by 25.26% to $36.1 million in 2022, then fell by 13.43% to $31.2 million in 2023, then decreased by 13.98% to $26.9 million in 2024, then decreased by 15.81% to $26.7 million in 2025.
- Its Operating Expenses was $26.7 million in Q3 2025, compared to $28.7 million in Q2 2025 and $28.9 million in Q1 2025.